60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP) is thrilled to announce that the Canadian Intellectual Property Office (CIPO) has granted them a patent that covers the use of tafenoquine for the prevention of malaria among individuals who have never before contracted the disease.
This new patent promises travelers as well as residents of Canada and the United States the strong protection they need to stay healthy, as they are often malaria naïve due to the lack of immunity towards the disease.
Traveling to a malaria-prone area? Get ahead of the game with ARAKODA, a FDA-approved regimen for malaria prevention that utilizes tafenoquine as its active molecule. Consisting of two 100 mg tablets taken once daily for three days prior to travel, and two tablets taken on a weekly basis during the course of travel up to six months, plus another two tablets taken the week following travel, ARAKODA provides comprehensive and reliable protection against malaria.
Get the peace of mind that comes with knowing you’re taking the necessary preventative measures – ARAKODA is available for adults in the U.S., though it is not currently available in Canada.
ARAKODA, the revolutionary malaria prevention drug utilizing tafenoquine, has recently been granted a Canadian patent—effective till December 2, 2035—securing exclusive use for the drug in preventing malaria in malaria-naive individuals. This follows the previously awarded U.S. patent, both covering the drug’s dosing regimen that has been accepted in the U.S. as a reliable means of malaria prevention.
Malaria is a life-threatening disease for those who are uninfected, and unfortunately, there is no vaccine available with approval from Canadian or U.S. regulatory authorities. The Centers for Disease Control and Prevention (CDC) and Health Canada advise travelers to take malaria chemoprophylactic drugs to reduce the risk of contracting the illness; a risk which is sadly becoming more present in the United States and Canada.
Despite these efforts, 1,823 malaria cases were reported in the U.S. in 2018 and 489 in Canada in 2014 — with 95% of Americans who contracted the illness coming from travel, and not taking or adhering to the prescribed chemoprophylactic drugs.
As local malaria transmission increases, such as the cases of eight Texas and Florida residents in 2023, raising the CDC’s health alert, it is even more essential for travelers to be aware and prepared.
About ARAKODA® (tafenoquine)
ARAKODA (tafenoquine) and KODATEF are now available at retail pharmacies, distributed through pharmaceutical wholesaler networks in the United States and Australia respectively. Developed by the Walter Reed Army Institute of Research in 2018, they offer the potential advantage of less-frequent dosing due to the long terminal half-life of tafenoquine (around 16 days!). However, ARAKODA is not suitable for everyone, so patients and physicians should consult the Important Safety Information before prescribing.